ASCO 2025: Nivolumab + chemoradiotherapy improves disease-free survival in Head and Neck Cancer

In this MEDtalk, Professor Jean Bourhis from CHUV, Lausanne, Switzerland, shares key findings from the phase III NIVOPOSTOP trial, presented at ASCO 2025. The study showed that adding nivolumab to standard of care chemoradiotherapy significantly improved 3-year disease-free survival in patients with resected high-risk head and neck squamous cell carcinoma, with manageable toxicity.